Abiopharma

🔍 ORBIMED ADVISORS LLC (Executive)

Company: Traws Pharma, Inc. (TRAW)

Report Date: 2026-04-16

Detailed Transactions and Holdings:

• Acquired 597,729 shares of Common Stock at $1.67 per share (Direct)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,203,250.00 | transaction_form_type: 4 | Footnotes: F3
• Acquired 597,729 shares of Series A Warrants (right to buy) at $1.673 per share (Derivative)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 597,729.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
• Acquired 597,729 shares of Series B Warrants (right to buy) at $1.673 per share (Derivative)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 597,729.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3
• Acquired 1,793,187 shares of Series C Warrants (right to buy) at $1.673 per share (Derivative)
  Date: 2026-04-16 | Code: P | equity_swap_involved: 0 | shares_owned_after: 1,793,187.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F3

Footnotes:

• F1: On April 15, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain investors (the "Investors"), including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on April 16, 2026 (the "Closing Date") Series A warrants, Series B warrants, and Series C warrants (collectively, the "Warrants") to purchase up to an aggregate of 2,988,645 shares. The price per Pre-Funded Warrant is $1.673.
• F2: The Warrants are exercisable pursuant to the conditions described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 15, 2026.
• F3: These securities are held of record by OrbiMed Private Investments VIII, LP ("OPI VIII"). OrbiMed Capital GP VIII LLC ("GP VIII") is the general partner of OPI VIII. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP VIII. By virtue of such relationships, GP VIII and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VIII. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI VIII.
• F4: This report on Form 4 is jointly filed by OrbiMed Advisors and GP VIII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.